Last reviewed · How we verify
NCT05811975
KSX01-TCRT Injection Project in Solid Tumors
EARLY_PHASE1 trial testing KSX01-TCRT injection in TCR-T Cells in 50 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | TCRx Therapeutics Co.Ltd |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 7 March 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- KSX01-TCRT injection — full drug profile →
Conditions studied
- TCR-T Cells — all drugs for TCR-T Cells →
- Refractory Solid Tumors — all drugs for Refractory Solid Tumors →
- Relapsed Solid Tumors — all drugs for Relapsed Solid Tumors →
Sponsor
TCRx Therapeutics Co.Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with TCR-T Cells or Refractory Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1\) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J, Xiao Z, Wang D, Jia L, et al · · 2023 · cited 52× · PMID 37649123 · DOI 10.1186/s12943-023-01844-5
Verify or expand the search:
- PubMed search for NCT05811975
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for TCR-T Cells
Currently open trials in the same condition.
- NCT05539833 — KSH01-TCRT Solid Tumors · EARLY_PHASE1 · recruiting
Other TCRx Therapeutics Co.Ltd trials
Trials by the same sponsor.
- NCT07275853 — Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07196579 — Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07260812 — KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · recruiting
- NCT05580796 — KSH01-R02-101 Solid Tumors · EARLY_PHASE1 · recruiting
- NCT05539833 — KSH01-TCRT Solid Tumors · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05811975 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TCRx Therapeutics Co.Ltd
- Last refreshed: 13 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05811975.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing